Durable Remission After Targeted Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Case Report
Daniel A Fox1, Deepak Bhamidipati2, Scott Kopetz3
1The Margaret M. and Albert B. Alkek Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Journal of Immunotherapy and Precision Oncology
|January 15, 2025
Summary
BRAF V600E-mutated colorectal cancer (CRC) patients can achieve durable responses with combined targeted therapy (vemurafenib plus cetuximab) and chemotherapy. This approach shows promise for advanced CRC, even with high disease burden.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- BRAF mutations activate the MAPK pathway, correlating with immune-activating colorectal cancer (CRC) subtypes.
- Targeted therapy combining anti-EGFR and anti-BRAF V600E agents improves outcomes in metastatic CRC but is often followed by disease progression.
Observation:
- A patient with metastatic, mismatch repair-deficient, BRAF V600E-mutated CRC presented with a high disease burden, including peritoneal involvement.
- This patient achieved a durable complete response to a regimen of vemurafenib, cetuximab, and chemotherapy.
Findings:
- The combination of vemurafenib (anti-BRAF V600E) and cetuximab (anti-EGFR) with chemotherapy demonstrated efficacy in a challenging CRC case.
- This case represents a robust response, contrasting with limited instances in recent clinical trials of similar combined therapies.
Implications:
- Combined targeted therapy and chemotherapy may offer a promising treatment strategy for BRAF V600E-mutated CRC.
- Further investigation into the immunogenic properties of BRAF mutations and combined treatment regimens is warranted for advanced CRC.
Related Concept Videos
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K